

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

219847Orig1s000

Trade Name: Arynta oral solution

Generic or Proper Name: Lisdexamphetamine dimesylate

Sponsor: Azurity Pharmaceuticals, Inc

Approval Date: June 16th, 2025

Indication: Treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder (BED)

CENTER FOR DRUG EVALUATION AND RESEARCH

219847Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) • Summary Review • Clinical • Non-Clinical • Statistical • Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

219847Orig1s000

APPROVAL LETTER



NDA 219847

NDA APPROVAL

Azurity Pharmaceuticals, Inc.
Attention: Ravindhar Gonti
Associate Director, Regulatory Affairs
8 Cabot Road, Suite 2000
Woburn, MA 01801

Dear Ravindhar Gonti:

Please refer to your new drug application (NDA) received August 16, 2024, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Arynta (lisdexamphetamine dimesylate) oral solution.

This NDA provides for the use of Arynta (lisdexamphetamine dimesylate) oral solution for treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder (BED).

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry, *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

CARTON AND CONTAINER LABELING

We acknowledge your June 9, 2025, submission containing final printed carton and container labeling.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Arynta (lisdexamphetamine dimesylate) oral solution shall be 18 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA; 21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirements for BED for this application because necessary studies are impossible or highly impracticable because there are too few patients with moderate-to-severe BED.

We are waiving the pediatric study requirements for birth to younger than 4 years of age with ADHD because necessary studies are impossible or highly impracticable because the diagnostic criteria and assessment measures for determining efficacy for the treatment of ADHD in children younger than 4 years old are not well defined, and pharmaceutical treatment in this age group is uncommon.

This product is appropriately labeled for use in ages 4 to 17 years of age for ADHD. Therefore, no additional studies are needed in this pediatric group.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry, *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website.⁶

If you have any questions, contact Pawanprit Singh, Regulatory Project Manager, at Pawanprit.singh@fda.hhs.gov or 240-402-8866.

Sincerely,

{See appended electronic signature page}

Bernard Fischer, MD
Deputy Director
Division of Psychiatry
Office of Neuroscience
Center for Drug Evaluation and Research

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

⁶ <https://www.uspnf.com/>

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BERNARD A FISCHER
06/16/2025 11:03:51 AM